BMY
Bristol Myers Squibb develops and commercializes pharmaceutical products across oncology, immunology, and cardiovascular disease, with approved commercial products including Opdivo (anti-PD-1 monoclonal antibody for oncology), Orencia (biologic for immunology), and Eliquis (small molecule anticoagulant), while maintaining a pipeline of late-stage and clinical-stage compounds facing typical drug development risks including efficacy and safety concerns, regulatory delays, manufacturing challenges, and reimbursement uncertainties. The company's future revenue depends on successful development and commercialization of new products to replace revenues lost when branded products lose patent exclusivity, with certain future key products expected to require FDA Risk Evaluation and Mitigation Strategies programs.